preloader

1952(E)

(Published in Part II, Section 3, Sub Section (ii) of the 
Gazette of India Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)

                                                                New Delhi, the 2nd June, 2016

ORDER

S.O.1952(E)  – In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No. Name of the Scheduled Formulation / Brand Name Strength Unit Manufacturer & Marketing Company respectively Retail Price (Rs.)
(1) (2) (3) (4) (5) (6)
1 Cefixime +
Ofloxacin Tablet
(Cefaclass – O Tablet)
Each film coated tablet contains:
Cefixime (as trihydrate) eq. to
Anhydrous Cefixime 200mg
Ofloxacin 200mg
1 Tablet M/s Scott Edil Advance Research
Lab. & Education Ltd.&
M/s Gem Mankind
9.86
2 Adapalene +
Benzoyl Peroxide Gel
Each gm contains:
Adapalene 0.1% w/w
Hydrous Benzoyl Peroxide eq. to
Anhydrous Benzoyl Peroxide 2.5% w/w
1 Gram M/s Apex Lab. Pvt. Ltd. 18.10
3 Diclofenac sodium Tablet
(Zeldinac 100 SR)
Each sustained release film coated
tablet contains:
Diclofenac Sodium-100mg
1 Tablet M/s Innova Captab &
M/s Leeford Healthcare Ltd.
4.28
4 Gliclazide+
Metformin HCl Tablet
(Azukon M OD 30)
Each uncoated bilayered tablet contains:
Gliclazide (as extended release)-30mg
Metformin HCl (as extended release)-500mg
1 Tablet M/s Ravenbhel Healthcare Pvt. Ltd. &
M/s Torrent Pharmaceuticals Ltd.
4.96
5 Gliclazide+
Metformin HCl Tablet
(Azukon M OD 60)
Each uncoated bilayered tablet contains:
Gliclazide (as extended release)-60mg
Metformin HCl (as extended release)-500mg
1 Tablet M/s Ravenbhel Healthcare Pvt. Ltd. &
M/s Torrent Pharmaceuticals Ltd.
7.98
6 Dextromethorphan Hydrobromide +
Chlorpheniramine Maleate syrup
Each 5ml contains:
Dextromethorphan Hydrobromide 10mg
Chlorpheniramine Maleate 2mg
1 ml M/s Apex Lab. Pvt. Ltd. 0.50
7 Paclitaxel (Protein bound particle)
for Injectable Suspension
Each vial contains:
Paclitaxel 100mg
Human Albumin
1 Vial M/s Beta Drugs Pvt. Ltd. &
M/s Cadila Pharmaceuticals Ltd.
11590.00
8 Escitalopram Oxalate +
Clonazepam Tablet
(Megapose-Plus New)
Each film coated tablet contains:
Escitalopram Oxalate eq. to Escitalopram 10mg
Clonazepam 0.5mg
1 Tablet M/s Windlas Biotech Ltd. &
M/s Magnet Labs. Pvt. Ltd.
8.62

NOTE :

  1. The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
  2. The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
  3. The retail price for a pack of the aforesaid formulations shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V as per paragraph 24 (2) of the DPCO, 2013.
  4. The above mentioned retail price is applicable only to the individual manufacturers/marketeers as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
  5. The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
  6. In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
  7. Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketeer prior to the above said date of notification, stand(s) superseded.

PN/164/32/2016/F

F.No. 8(32)/2016/D.P./NPPA-Div.II

(BALJIT SINGH)
Assistant Director
National Pharmaceutical Pricing Authority

Last Page Updated: 09-01-2019